Free Trial

Zymeworks (ZYME) Competitors

Zymeworks logo
$12.84 -0.06 (-0.43%)
Closing price 07/3/2025 01:45 PM Eastern
Extended Trading
$12.84 0.00 (0.00%)
As of 07/3/2025 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZYME vs. PTGX, AAPG, SRRK, MTSR, KYMR, VKTX, MOR, CRNX, ALVO, and MLTX

Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Metsera (MTSR), Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

Zymeworks vs. Its Competitors

Zymeworks (NYSE:ZYME) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Zymeworks has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500.

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Zymeworks. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 3 mentions for Zymeworks. Protagonist Therapeutics' average media sentiment score of 0.54 beat Zymeworks' score of 0.53 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zymeworks
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protagonist Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 1.9% of Zymeworks shares are held by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zymeworks currently has a consensus price target of $21.00, indicating a potential upside of 63.62%. Protagonist Therapeutics has a consensus price target of $66.10, indicating a potential upside of 29.10%. Given Zymeworks' higher probable upside, equities research analysts clearly believe Zymeworks is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
Protagonist Therapeutics
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.00

Protagonist Therapeutics has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zymeworks$93.38M9.56-$118.67M-$1.49-8.61
Protagonist Therapeutics$434.43M7.30$275.19M$0.7568.27

Protagonist Therapeutics has a net margin of 27.04% compared to Zymeworks' net margin of -182.75%. Protagonist Therapeutics' return on equity of 9.22% beat Zymeworks' return on equity.

Company Net Margins Return on Equity Return on Assets
Zymeworks-182.75% -23.00% -18.04%
Protagonist Therapeutics 27.04%9.22%8.31%

Summary

Protagonist Therapeutics beats Zymeworks on 14 of the 16 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZYME vs. The Competition

MetricZymeworksPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$893.02M$790.73M$5.54B$20.72B
Dividend YieldN/A4.84%5.24%3.71%
P/E Ratio-8.561.3527.4328.09
Price / Sales9.56226.97416.8738.30
Price / CashN/A23.4436.8922.53
Price / Book1.946.298.034.58
Net Income-$118.67M-$27.73M$3.18B$986.06M
7 Day Performance2.93%1.82%2.88%2.79%
1 Month Performance5.81%9.90%3.69%5.46%
1 Year Performance44.54%10.79%36.02%15.06%

Zymeworks Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZYME
Zymeworks
2.0055 of 5 stars
$12.84
-0.4%
$21.00
+63.6%
+53.0%$893.02M$93.38M-8.56460Analyst Forecast
PTGX
Protagonist Therapeutics
2.1369 of 5 stars
$53.36
+0.0%
$66.10
+23.9%
+48.4%$3.31B$434.43M71.15120
AAPG
Ascentage Pharma Group International
N/A$37.15
-0.6%
N/AN/A$3.26B$134.35M0.00600Gap Up
SRRK
Scholar Rock
3.3493 of 5 stars
$33.28
-2.2%
$42.67
+28.2%
+355.0%$3.23B$33.19M-13.15140
MTSR
Metsera
N/A$29.00
-2.0%
$55.00
+89.7%
N/A$3.11BN/A0.0081
KYMR
Kymera Therapeutics
3.1715 of 5 stars
$46.29
+0.9%
$59.82
+29.2%
+48.6%$2.99B$47.07M-14.93170Analyst Forecast
Insider Trade
VKTX
Viking Therapeutics
4.3628 of 5 stars
$24.86
-4.4%
$87.15
+250.6%
-44.2%$2.92BN/A-21.6220Trending News
Insider Trade
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730News Coverage
CRNX
Crinetics Pharmaceuticals
3.5658 of 5 stars
$29.91
-0.8%
$74.56
+149.3%
-32.4%$2.82B$1.04M-7.83210
ALVO
Alvotech
3.5338 of 5 stars
$9.13
-2.4%
$18.00
+97.2%
-24.4%$2.82B$491.98M24.681,032
MLTX
MoonLake Immunotherapeutics
2.1822 of 5 stars
$44.87
+3.1%
$78.71
+75.4%
+9.9%$2.78BN/A-19.512News Coverage

Related Companies and Tools


This page (NYSE:ZYME) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners